Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesBosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
Vascular Health and Risk Management, 08/05/09
Valerio CJ et al. – The EARLY trial exclusively enrolled functional class II patients and assessed hemodynamics at 6 months. Though significant, the reduction in pulmonary vascular resistance is merely a surrogate marker for the intended aim of delaying disease progression. Significant adverse effects associated with bosentan include edema, anemia and transaminase elevation. These may preclude a long duration of treatment.
Related Articles
Bosentan: A Review of its Use in the Management of Mildly Symptomatic Pulmonary Arterial Hypertension
American Journal of Cardiovascular Drugs, 10/08/09
Relevance Score: 87%
TNF-alpha-induced GM-CSF Release from Human Airway Smooth Muscle Cells Depends on Activation of an ET-1 Autoregulatory Positive Feedback Mechanism
Thorax, 11/09/09
Relevance Score: 84%
Safe Treatment of Pulmonary Hypertension With Bosentan in a Patient With Moyamoya Disease and Cerebral Ischemia
Journal of Child Neurology, 10/27/09
Relevance Score: 83%
Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease
British Journal of Haematology, 10/05/09
Relevance Score: 82%
Effects of an Endothelin Receptor Antagonist on a Model of Hypertensive Retinopathy
Ophthalmic Research, 10/20/09
Relevance Score: 80%
Today in CV/Thromboembolic...keeping you current
Receive free subspecialty "5-minute updates" via email
High frequency oscillatory ventilation in children: an overview
Respiratory Medicine CME, 12/04/09
Intrapleural hemorrhage after administration of tPA: a case report and review of the literature
Therapeutic Advances in Respiratory Disease, 12/04/09
Telangiectases in scleroderma: A potential clinical marker of pulmonary arterial hypertension
Journal of Rheumatology, 12/03/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 12/04/09
Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD: a systematic review and meta-analysis
European Respiratory Journal , 12/03/09
Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis
Journal of Cystic Fibrosis , 12/02/09
Sponsor
Article Search
Sponsor